The newly released data indicate that the Endeavor stent offers durable efficacy out to four years of follow-up, with no new events requiring target lesion revascularization (TLR) between years three and four. They also reinforce the long-term safety record of the Endeavor stent, which was associated with no new episodes of stent thrombosis over the same period.
Compared with the company’s Driver bare-metal stent (the control in Endeavor II), these trial results show a lower rate of target vessel failure (TVF) for patients treated with the Endeavor stent, due largely to a diminished rate of target vessel revascularization (TVR).
Jean Fajadet of the Clinique Pasteur Unite de Cardiologie Interventionnelle in Tolouse, France, who presented the data, said: “As the duration of follow-up in Endeavor II grows, so too does our confidence in the enduring safety and effectiveness of the Endeavor stent. The durability of this device’s performance is remarkable based on these four-year results, which show low rates of late adverse events.”